PGL-III, a Rare Intermediate of Phenolic Glycolipid Biosynthesis, Is a Potent Mincle Ligand
Overview
Authors
Affiliations
Although leprosy (Hansen's disease) is one of the oldest known diseases, the pathogenicity of () remains enigmatic. Indeed, the cell wall components responsible for the immune response against are as yet largely unidentified. We reveal here phenolic glycolipid-III (PGL-III) as an -specific ligand for the immune receptor Mincle. PGL-III is a scarcely present trisaccharide intermediate in the biosynthetic pathway to PGL-I, an abundant and characteristic glycolipid. Using activity-based purification, we identified PGL-III as a Mincle ligand that is more potent than the well-known trehalose dimycolate. The cocrystal structure of Mincle and a synthetic PGL-III analogue revealed a unique recognition mode, implying that it can engage multiple Mincle molecules. In Mincle-deficient mice infected with , increased bacterial burden with gross pathologies were observed. These results show that PGL-III is a noncanonical ligand recognized by Mincle, triggering protective immunity.
Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants.
Weth A, Dangerfield E, Timmer M, Stocker B Vaccines (Basel). 2025; 12(12.
PMID: 39771982 PMC: 11680293. DOI: 10.3390/vaccines12121320.
Srivatsav A, Kapoor S ACS Appl Bio Mater. 2023; 6(12):5555-5562.
PMID: 38015441 PMC: 7617140. DOI: 10.1021/acsabm.3c00748.